My name is Greg.

Greg's portrait

I’m 58 years old and an avid runner. For years, PNH took the best out of my life. Now I’m taking it back.

1     2     3     Next

You would never know from looking at Greg that he’s suffered from paroxysmal nocturnal hemoglobinuria (PNH) for more than a decade. Greg is a fit and optimistic 58-year-old who has the energy to exercise daily and tackle projects around the house. Thanks to Soliris®, an effective treatment for PNH, Greg has control over his symptoms. He’s no longer suffering. And it’s about time.

It was the summer of 1995 when Greg, a runner and the picture of health, first noticed that his urine was dark and red. As a healthcare professional, Greg knew something was very wrong. He collected a sample of his urine and brought it to his urologist, who recommended further tests.

A litany of tests were run on Greg’s blood, but no diagnosis could be determined. So he was sent back to work at his dental practice. Six weeks later at a follow-up visit, Greg’s doctor tested his blood once again. This time he discovered that Greg’s serum and red blood cells wouldn’t separate. Still concerned as to what the problem might be, his doctor referred him to a hematologist.

So many tests had been run that the most obvious conditions were ruled out, allowing Greg’s hematologist to focus on more obscure possibilities. That’s when he finally got his diagnosis of PNH. Greg’s own body was attacking and destroying his red blood cells through a process called hemolysis.

1     2     3     Next





IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).

Please see full prescribing information for SOLIRIS, including boxed WARNING regarding serious meningitis.


References: 1. de Castro CM. Paroxysmal Nocturnal Hemoglobinuria (PNH) Basic Explanations. Annapolis, MD: Aplastic Anemia & MDS International Foundation; 2006. 2. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243. 3. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137:181-192. 4. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653-1662. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria [published online ahead of print August 16, 2007]. Blood. 2007;110:4123-4128. doi:10.1182/blood-2007-06-095646. 6. Data on file, Alexion Pharmaceuticals Inc. 7. Soliris® [package insert]. Cheshire, CT: Alexion Pharmaceuticals Inc; 2008.